|
1. BIOLOGIE
|
|
|
|
2.13 ETIOLOGIE - NDMA
|
|
|
|
3.1.1 PRÉVENTION - TABAC - E-CIGS
|
|
|
|
4.1 DÉP., DIAG. & PRONO. - PROSTATE
|
|
|
|
4.2 DÉP., DIAG. & PRONO. - GÉNOME
|
|
|
|
4.9 DÉP., DIAG. & PRONO. - SEIN
|
|
|
|
5.12.10 IMMUNOTHÉRAPIES - FUSIONS ET ACQUISITIONS
|
|
|
|
|
|
5.12.11 IMMUNOTHÉRAPIES - PRÉ-CLINIQUE
|
|
|
Vitamin C and Immuno-oncology [In The Pipeline]
|
|
|
|
|
|
But if this work makes some headlines of the “Linus Pauling was right” sort, don’t believe them. Pauling was right about a lot of things, but like many bold scientific thinkers, when he was wrong he was wrong in grand fashion. And he was wrong about vitamin C and cancer.
|
|
|
|
|
|
|
5.12.2 IMMUNOTHÉRAPIES - CAR-T, THÉRAPIES CELLULAIRES
|
|
|
|
|
5.12.5 IMMUNOTHÉRAPIES - PHARMA
|
|
|
|
|
5.12.5.1.1 IMMUNOTHÉRAPIES - BIOTECH - IMMUNOCORE
|
|
|
|
|
5.12.5.1.2 IMMUNOTHÉRAPIES - BIOTECH - XILIO
|
|
|
|
|
|
5.2 PHARMA
|
|
|
|
|
5.2.6 PHARMA - BIOTECH
|
|
|
|
5.2.6.1 PHARMA - BIOTECH - KARYOPHARM
|
|
|
|
|
|
5.3.4 TRAITEMENTS - AMM (FDA, EMA,...)
|
|
|
|
|
FDA approves isatuximab-irfc for multiple myeloma [FDA]
|
|
|
|
|
|
ICARIA-MM (NCT02990338), a multicenter, multinational, randomized, open-label, two-arm, phase 3 study in 307 patients with relapsed and refractory multiple myeloma who had received at least two prior therapies including lenalidomide and a proteasome inhibitor.
|
|
|
|
|
|
|
6. LUTTE CONTRE LES CANCERS
|
|
|